5% Imiquimod Suppositories Decrease the DNA Load of Intra-anal HPV Types 6 and 11 in HIV-Infected Men After Surgical Ablation of Condylomata Acuminata

Human papillomavirus-associated induction of human β-defensins in anal intraepithelial neoplasia

“…For HPV typing, internal, biotinylated A6/A8 PCR products were hybridized with 37 type‐specific digoxigenin‐labelled oligonucleotide probes in an enzyme immunoassay 15,19 . HPV DNA loads were determined by real‐time PCRs, with type‐specific primers and probes for HR α‐HPV types 16, 18, 31 and 33 and for LR α‐HPV types 6 and 11, as previously reported 20,21 . HPV DNA loads were expressed as HPV DNA copies per β‐globin gene copy.…”

German‐Austrian guidelines on anal dysplasia and anal cancer in HIV‐positive individuals: prevention, diagnosis, and treatment

“…In an early prospective pilot study on imiquimod treatment of AIN, 28 HIV‐positive MSM with perianal or intraanal dysplasia were included, and therapy was performed for 16 weeks with either 5 % imiquimod cream (perianal) or imiquimod‐containing suppositories (intraanal) as previously reported . Prior to therapy, all patients had been infected with (often multiple) HR‐HPV types.…”

Deutsch‐Österreichische S2k‐Leitlinie: anale Dysplasien und Analkarzinome bei HIV‐Infizierten: Prävention, Diagnostik und Therapie

“…In der ersten prospektiven Pilotstudie zu Imiquimod bei AIN wurden 28 HIV‐positive MSM mit perianaler und intraanaler Dysplasie eingeschlossen und über 16 Wochen mit 5 % Imiquimod‐Creme (perianal) oder Imiquimod‐Zäpfchen (intraanal), wie vorab beschrieben, behandelt . Bei allen Patienten zeigte sich vor Therapie eine Infektion mit (zum Teil multiplen) HR‐HPV‐Typen.…”